The Map and the Territory Updated- GOPH, HMNY, YAYO, GENI, BOPT, FTMK & USXP(!)

Now updated to include Darren Dunckel, scum stock lawyer Stephen Fleming, links to notorious stock promotion Universal Express (USXP), and some very bad Russians (Vaynters, Guss) and Israelis (Attia, Schnapp) living in LA.

GOPH-Map

More on Gopher Protocol to come.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.
Advertisements

Stem cell guns, Harmel Rayat, and the return of Reg S(cam) – RCAR, WNDW, OCTL

Back in the 90s and early 00s a very common con was the “Reg S” scam. Using an exemption from the registration requirements companies could sell stock with virtually no disclosure, nor oversight. The catch, the shares could only be sold to non-US persons or institutions. Americans were forbidden to purchase Reg S stock.

Boiler rooms would buy huge blocks of Reg S stock at massive discounts from the trading price of the shares on the open market. Then, some of the stock would be spread around to various nefarious stock promoters to create demand and volume.

The boiler rooms would then furiously call foreigners offering them shares of hot “US-listed” company X. Even better, the call scripts would read, is that these shares are available at a discount, but only if you buy now.

As a hypothetical example, the boiler room baddies buy stock from a company, or from insiders, at $1, while the shares were actually trading at $4, and would offer them to the suckers at $3, pocketing the $2 “rip“.

But what’s the harm, you ask? The buyer still got a share of stock at $3, and the market price is $4 How can he lose?

(more…)

The Map and the Territory – GOPH, HMNY, YAYO, GENI, BOPT

Just for a start….

GOPH-Map

For more on Gopher Protocol, see yesterday’s post.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

It has “Gopher Guts” – GOPH, MOBQ

Before we begin, do you know about Sony guts?

If the rambling, raving, Israeli CTO, Dr. Danny Rittman, at Southern California reverse-merger company Gopher Protocol (GOPH), is to be believed, it seems that almost everything will one day have Gopher guts inside. Pet trackers, cell phones, even cryptocoins!

But one thing that is already stuffed to the gills with Gopher guts, is Long Island penny stock Mobiquity (MOBQ). Back in June of this year they issued a curious press release highlighting an even more curious transaction.

Glen Eagles Acquisitions LP Adds Mobiquity Technologies to its Portfolio of
Companies focusing on IoT, AI and Mobile Technologies

NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) — Mobiquity Technologies, Inc.
(OTCQB:MOBQ), a leading mobile location data intelligence company, is pleased
to announce a strategic investment by Glen Eagles Acquisitions LP. GEA is a company focused on building and acquiring businesses within the
Internet of Things (IoT), Artificial Intelligence (AI) and Mobile Technologies
Industries.

Quite a description of Glen Eagles. If it sounds familiar, that might be because the description of GOPH is almost exactly the same.

aboutGOPH\

Now, what is this “strategic investment” that the Eagles are making into MOBQ?

(more…)

When Prophecy Fails – Geron Edition (GERN)

Sometimes, we at BuyersStrike! HQ come across true cult stocks. Not the wildly popular, flavor of the moment, media darling stocks, but the People’s Temple or Heaven’s Gate of stocks. Smaller groups of fanatical retail investors make up the shareholder base, without attention from the broader market. And regardless of how much dis-confirming evidence one presents to the cult members, few (if any) will heed the warning. Most prefer to take the potion like they did in ancient Greece, and step over quietly. They are not committing investing suicide; it’s a revolutionary act!

(If one has read “When Prophecy Fails”, by Festinger and Riecken, the following should be familiar. If one has not, it is highly recommended, along with the other works on the BuyersStrike! Bookshelf.)

In psychology, cognitive dissonance is the mental anguish experienced by one who holds a belief contrary to overwhelming evidence. For stuckholders in cult stock Geron (GERN), this belief is:

(more…)

Echo Therapeutics: The Final Chapter (ECTE)

When this blog first started, in 2011, our very first post detailed the sorry state of Echo Therapeutics. Sad to say, 6 years later this obvious fraud still trades, albeit on its last legs at 4c per share or so.

From a recent 8K filing:

Due to the financial condition of Echo Therapeutics, Inc. (the “Company”), the Company was unable to make payment on $1,787,000 of the 10% senior secured convertible notes of the Company due on January 28, 2017 (the “January Notes”). An additional $3,361,620 in principal amount of 10% senior secured convertible notes of the Company matures on May 3, 2017 (the “May Notes” and together with the January Notes, the “Notes”). The Company has been engaged in prolonged discussions to obtain new financing and obtain appropriate forbearance and/or waivers from the investors holding Notes. To date, the Company has been unsuccessful in raising financing and, while the Investors have not taken any action against the Company, the Company has not yet received any formal forbearance and/or waiver from the Investors. The Company has been forced to reduce its staff down to one employee, Alan Schoenbart, the Company’s Chief Executive and Chief Financial Officer, who has been working without pay. Further, the Company has been unable to pay rent at its corporate and research facilities, which will more than likely result shortly in eviction proceedings. Additionally, the Company’s patents are at risk.

Victory is sweet.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Sign Me Up, Neratinib Edition: A Guest Post from B4UConsent – PBYI

[Editors Note – The following is a guest post from @B4UConsent, a real life patient with tremendous insight into drug development from both the patient and the clinical trial management perspectives. Follow her blog and on Twitter.]

Puma Biotech (PBYI) announced last week that their neratinib NDA was accepted for review [http://www.pumabiotechnology.com/pr20160920.html] by the FDA, raising the odds that someday soon, breast cancer patients who have almost no risk of disease recurrence will continue to have almost no risk of disease recurrence, all while gaining all the pleasures of unavoidable diarrhea and a risk of “fecal incontinence.” Sleep easy, my fellow HER2-positives, but don’t forget to dose up the Imodium first.

(more…)